Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue
Laiba Immad
Wed, February 18, 2026 at 2:32 PM GMT+9 2 min read
In this article:
PBH
-0.78%
Prestige Consumer Healthcare Inc. (NYSE:PBH) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)'s Quarterly Revenue
Prestige Consumer Healthcare Inc. (NYSE:PBH) stands fifteenth on our list of best healthcare stocks.
TheFly reported on February 6 that Canaccord reduced its price target on PBH to $86 from $88 and maintained a Buy rating on the shares. The change came after the company reported fiscal third-quarter sales of $283.4 million, a 2.4% year-over-year decline. This amount was roughly in line with company projections and came in just over the $282.0 million that the Street had anticipated. According to management, the Clear Eyes brand’s supply issues were the main cause of the sales drop.
Moreover, on February 5, Prestige Consumer Healthcare Inc. (NYSE:PBH) reported third-quarter net income, which totaled $46.7 million, while adjusted net income reached $54.9 million. Diluted EPS of $0.97, while adjusted diluted EPS came in at $1.14, compared with $1.22 in the same quarter last year. The company also finalized the acquisition of Pillar5 Pharma and repurchased about 0.8 million shares during the quarter. While maintaining projections for free cash flow of at least $245 million, the corporation also reduced its fiscal 2026 sales outlook to about $1.1 billion.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is a U.S. over-the-counter healthcare company that markets and innovates trusted wellness brands and continuously improves products to meet evolving consumer needs while expanding its portfolio and global reach in OTC care.
While we acknowledge the potential of PBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info